Pharmacotherapy for obesity

Lisa M. Neff*, Louis J. Aronne

*Corresponding author for this work

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Obesity is a chronic metabolic disorder that affects one third of American adults. Modest weight losses of just 5% to 10% of body weight, which are achievable with lifestyle modification and pharmacotherapy, can lead to remarkable improvements in many obesity-associated co-morbidities, including dyslipidemia, hypertension, and type 2 diabetes. In this review, the indications for pharmacotherapy and the goals of treatment are discussed, and current and future pharmacologic approaches to the treatment of obesity are examined. Current pharmacologic therapies for obesity are limited, but recent advances in our understanding of the complex and overlapping endocrine pathways that regulate body weight have led to new opportunities for antiobesity drug development. Important drug targets that are highlighted in this review include adipocyte-derived hormones, hypothalamic neuropeptides, and gastrointestinal hormones.

Original languageEnglish (US)
Pages (from-to)454-462
Number of pages9
JournalCurrent atherosclerosis reports
Volume9
Issue number6
DOIs
StatePublished - Dec 1 2007

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pharmacotherapy for obesity'. Together they form a unique fingerprint.

  • Cite this